Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Revision History For: Corautus Genetics (CAQ)

11 Jan 2006 09:01 AM <--

Return to Corautus Genetics (CAQ)

Corautus Genetics was created to capitalize on the complementary strengths of GenStar and VGI to accelerate the development of a later stage genetic therapy for cardiovascular disease. The focus of the company's efforts will be the clinical development of gene therapy products using Vascular Endothelial Growth Factor 2 (VEGF-2), a vascular growth factor gene.